Sanyou Biopharmaceuticals announced that it had signed a strategic cooperation agreement with Huadong Medicine with regard to cooperative development of innovative double antibodies against high-quality targets and ADC molecules to accelerate the marketing of a new generation of anti-tumor drugs.
On November 20, 2020, Sanyou Biopharmaceuticals, a biotechnology company that focuses on the integrated solution for innovative antibody drug R&D, announced that it had signed a strategic cooperation agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963) (Huadong Medicine) with regard to cooperative development of innovative double antibodies against high-quality targets and ADC molecules to accelerate the marketing of a new generation of anti-tumor drugs.
With an
independently integrated development platforms for high-quality antibody drugs
and an internationally leading series of sub-trillion antibody
libraries, Sanyou Biopharmaceuticals has the capability to
efficiently construct and screen new double antibodies against specific targets
and ADC molecules; Huadong Medicine possesses profound technical accumulation,
clinical insight, and business integration ability in the field of anti-tumor
and has the strength to transform innovative molecules into leading drugs and
promote their rapid marketing.
This
cooperation is an important layout of Huadong Medicine to accelerate the
strategic transformation of innovative drugs, as well as a breakthrough to promote the strategy
of innovative antibody drugs by Sanyou Biopharmaceuticals with leading
pharmaceutical companies. Through long-term friendly cooperation, both parties
hope to accelerate the marketing of innovative drugs and benefit patients around the
world.
About Huadong Medicine
Founded
in 1993 and ranked as top 10 in Fortune China in 2020, Huadong Medicine
(SZ.000963),is a publicly-traded pharmaceutical company which integrates
R&D, manufacturing, sales and business. With marketing channels in
tens of thousands of large and medium-sized hospitals,Huadong Medicine has more
than 10,000 employees in China, including more than 1,000 R&D personnel,
covering all R&D links of drug discovery, preclinical study, clinical
study, CMC and registration. Focusing on the innovation and transformation
strategy, it is committed to building a deep R&D pipeline for innovative
products of tumor, endocrine and autoimmune diseases with the help of R&D
resources and management capabilities as well as rich partners with cutting-edge
technical means.